Targets › APELIN
1 program from 1 company in 1 trial: 1 Phase 2; Cardiovascular; next expected readout Dec 2026.
Open in Phaseline: the race on APELIN, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Cambridge University Hospitals NHS Foundation Trust | Apelin Apelin receptor agonist; activates G protein-coupled receptor to inhibit insulin secretion | APELIN | Phase 2 | Cardiovascular Diseases | Dec 2026 |
Cardiovascular Diseases (1)
small molecule (1)
Cambridge University Hospitals NHS Foundation Trust (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.